A real-world investigation has found that CDK4/6 inhibitor treatment outcomes are worse in patients with germline BRCA mutation–positive metastatic breast cancer than in patients with germline BRCA wild-type disease and unclear germline BRCA status, implying possible changes in tumor biology. Read More ›

Clinical studies have demonstrated that olaparib is clinically efficacious in patients with germline BRCA mutation–positive, HER2-negative metastatic breast cancer in a setting closely resembling the real world. Read More ›

Patients with HR-positive, HER2-negative metastatic breast cancer are more likely to have disease response to palbociclib plus letrozole versus letrozole alone, according to a real-world study. However, in real-world practice, there is less information on the tumor response of palbociclib plus an aromatase inhibitor versus an aromatase inhibitor alone. Read More ›

Earlier this year, the independent data monitoring committee concluded that the OlympiA trial crossed the superiority boundary for its primary end point of invasive disease-free survival and demonstrated a sustainable, clinically relevant treatment effect for olaparib versus placebo in patients with germline BRCA mutation–positive, high-risk, HER2-negative, early breast cancer. Read More ›

A completion of local treatment and neoadjuvant or adjuvant chemotherapy results in significantly longer survival, free of invasive or distant disease than placebo in patients with high-risk, HER2-negative early breast cancer, with germline BRCA1 or BRCA2 pathogenic variants. Read More ›

Despite their frailty and comorbidities in the elderly patient population, palbociclib was proven to be a well-tolerated treatment in elderly patients with advanced, ER-positive, HER2-negative breast cancer. Read More ›

Dalpiciclib plus fulvestrant has been clinically demonstrated to significantly improve progression-free survival and reduce the risk for disease progression or death. Read More ›

Abemaciclib plus nonsteroidal aromatase inhibitors were shown to be a successful initial treatment in a Japanese subpopulation, with a tolerable safety profile, consistent with findings in the whole population in treating patients with HR-positive, HER2-negative advanced breast cancer. Read More ›

Olaparib monotherapy has shown promising clinical results in treatment-naïve TNBC with germline or somatic homologous repair deficiency, with fewer adverse events compared with traditional chemotherapy. Read More ›

CDK4/6 inhibitors in combination with antiestrogen therapy are the standard of care for HR-positive, HER2-negative advanced breast cancer. However, a diverse landscape of resistance to these therapies exists, which has resulted in precision-guided therapeutic strategies that are under active clinical development. Read More ›